文献速递其他结缔组织病

特发性炎性肌病死亡率:瑞典全国人群队列研究

Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study.
PubMed 文献 · Ann Rheum Dis · 2017-08-16

该研究基于瑞典全国医疗登记数据,纳入2002至2011年诊断的716例特发性炎性肌病(IIM)患者和7100名一般人群对照,随访至死亡登记。结果显示IIM患者死亡率为60/1000人年,一般人群为20/1000人年,总体死亡风险比为3.7(95%CI 3.2-4.4),诊断后第一年内死亡风险比高达9.6(95%CI 6.9-13.5)。

要点

  • IIM患者总体死亡风险约为一般人群的3.7倍(HR 3.7,95%CI 3.2-4.4)。
  • 诊断后第一年内死亡风险显著升高,HR达9.6(95%CI 6.9-13.5)。
  • 恶性肿瘤、循环系统和呼吸系统疾病是常见死因。

核心结论

  • 当代IIM患者死亡率较一般人群显著增加,且诊断后第一年内即出现死亡风险升高。

研究设计与样本

  • 基于瑞典全国医疗登记数据的 population-based 队列研究,纳入2002至2011年诊断的716例IIM患者及7100名一般人群对照,链接死亡原因登记进行随访。

主要发现

  • 随访期间IIM患者死亡224例(31%),一般人群死亡870例(12%)。
  • IIM死亡率为60/1000人年,一般人群为20/1000人年。
  • 诊断后1年累积死亡率IIM为9%,一般人群为1%。
  • IIM与一般人群比较的总体死亡风险比HR为3.7(95%CI 3.2-4.4)。
  • 诊断后第一年内死亡风险比HR为9.6(95%CI 6.9-13.5),病程超过10年后HR平台期约2但无统计学显著性。

关键数值与推荐

  • IIM患者总体死亡风险比HR 3.7(95%CI 3.2-4.4)。
  • 诊断后第一年内死亡风险比HR 9.6(95%CI 6.9-13.5)。
  • 诊断后1年累积死亡率IIM 9%,一般人群1%。

临床怎么用

  • IIM诊断后第一年内应加强 vigilance,密切监测死亡风险。
  • 关注恶性肿瘤、循环系统及呼吸系统疾病等常见死因的筛查与管理。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Patients with idiopathic inflammatory myopathies (IIMs) suffer an increased burden of comorbidities, but data on mortality in recently diagnosed IIM are conflicting. Also, little is known when, if ever, in relation to IIM diagnosis, mortality is increased. METHODS: A population-based IIM cohort of patients diagnosed between 2002 and 2011 and general population comparators were identified using healthcare registers. They were linked to the cause of death register for follow-up. RESULTS: 224 (31%) of the 716 patients with IIM and 870 (12%) of the 7100 general population died during follow-up. This corresponded to a mortality rate of 60/1000 person-years in IIM and 20/1000 person-years in the general population. The cumulative mortality at 1 year after diagnosis was 9% in IIM and 1% in the general population, and increased in both IIM and the general population with time. The overall hazard ratio (HR) 95%CI of death comparing IIM with the general population was 3.7 (3.2 to 4.4). When we stratified on time since diagnosis, we noted an increase in mortality already within the first year of diagnosis compared with the general population, HR 9.6 (95% CI 6.9 to 13.5). This HR then plateaued around 2 after >10 years with the disease, although the estimates were not statistically significant. Malignancies, diseases of the circulatory and respiratory system were common causes of death. CONCLUSION: Mortality is increased in patients with contemporary IIM. The increased mortality was noted within a year of diagnosis, which calls for extra vigilance during the first year of IIM diagnosis.

来源:Ann Rheum Dis,查看原文。版权归原作者所有。

引用

  1. Dobloug GC, Svensson J, Lundberg IE, et al. Mortality in idiopathic inflammatory myopathy: results from a Swedish nationwide population-based cohort study. Ann Rheum Dis. 2017. PMID: 28814428. doi:10.1136/annrheumdis-2017-211402

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。